Global Neglected Tropical Diseases Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Neglected Tropical Diseases Treatment Market Size

• The Global Neglected Tropical Diseases Treatment Market size was valued at USD 3.79 billion in 2024 and is expected to reach USD 7.9 Billion by 2032, at a CAGR of 4.3% during the forecast period
• The market growth is largely driven by ongoing advancements in global health initiatives and biotechnology, enhancing the clinical application of Neglected Tropical Diseases (NTDs) Treatment therapies for conditions such as leishmaniasis, Chagas disease, schistosomiasis, and lymphatic filariasis.
• Additionally, rising awareness of NTDs, growing investments from international health organizations, and supportive regulatory and funding frameworks in low- and middle-income countries are positioning NTD treatment solutions as critical tools in the fight against poverty-related infectious diseases. These combined factors are accelerating research, clinical trials, and drug development efforts, significantly propelling the growth of the Global Neglected Tropical Diseases Treatment Market.

Neglected Tropical Diseases Treatment Market Analysis

• Neglected Tropical Diseases (NTDs) Treatment therapies, particularly those focused on antimicrobial, antiparasitic, and immunomodulatory strategies, are becoming increasingly essential in global health due to their ability to address chronic infections and long-term complications in underserved populations. These treatments are gaining traction in both research and clinical settings as global health priorities shift toward eliminating the burden of NTDs.
• The rising demand for NTDs treatment solutions is primarily driven by increased global awareness, international health initiatives (such as those led by WHO), and investments from both public and private sectors aimed at eradicating diseases like schistosomiasis, leishmaniasis, and lymphatic filariasis.
• North America dominates the Global Neglected Tropical Diseases Treatment Market with the largest revenue share of 40.01% in 2025, attributed to strong R&D infrastructure, funding support from global health organizations, and a concentration of biotech and pharmaceutical firms engaged in infectious disease drug development—particularly in the U.S.
• Asia-Pacific is expected to be the fastest-growing region in the Neglected Tropical Diseases Treatment Market during the forecast period, fueled by high disease prevalence, expanding access to healthcare services, and increased regional investment in NTD research and development.
• The Mediterranean Fever segment is projected to lead the Neglected Tropical Diseases Treatment market with a 43.2% share in 2025, driven by increasing clinical adoption of antileishmanial therapies, robust clinical trial activity, and the urgent need for effective, standardized treatment options. Its prevalence across tropical and subtropical regions, combined with growing support from global health organizations and pharmaceutical partnerships, is fueling widespread implementation and market dominance within the NTD treatment landscape.

Report Scope and Neglected Tropical Diseases Treatment Market Segmentation    

Neglected Tropical Diseases Treatment Market Trends

“Growing Integration of Novel Drug Delivery Systems and Biologics in NTD Treatment Development”

• A significant trend in the Global Neglected Tropical Diseases Treatment Market is the growing integration of novel drug delivery systems and biologics. These systems are being developed to improve the efficacy and precision of treatments for neglected tropical diseases (NTDs) by enhancing the way therapies are delivered to the affected tissues and organs, leading to better patient outcomes and minimizing side effects.
  • For instance, Novartis is exploring the use of biologic agents and targeted drug delivery systems to treat diseases like leishmaniasis and malaria. Their research aims to optimize drug absorption and ensure the controlled release of active ingredients over an extended period, which is crucial in improving the therapeutic efficiency of treatments for chronic NTDs.
• These innovative delivery methods, such as nanoparticle-based drug delivery and injectable biologics, allow for better tissue targeting and sustained drug action, particularly in conditions where conventional oral treatments or standard biologics have limited success. By providing controlled, localized treatment, these advanced systems can enhance therapeutic effectiveness while reducing the risk of drug resistance.
• Moreover, the use of biologics, such as monoclonal antibodies and engineered proteins, is gaining traction in the fight against NTDs, as they offer higher specificity and targeted action against pathogens without harming healthy tissue. With continued advancements in biotechnology and drug formulation techniques, these innovations are expected to revolutionize the way neglected tropical diseases are treated in both endemic and emerging regions.
• This trend of advanced drug delivery systems and biologics represents a promising direction in improving accessibility, treatment adherence, and outcomes for populations suffering from neglected tropical diseases. As pharmaceutical companies and research organizations focus on refining these technologies, they hold the potential to significantly enhance the Global Neglected Tropical Diseases Treatment Market's effectiveness and scope in the near future.

Neglected Tropical Diseases Treatment Market Dynamics

Driver

“Increasing Government and NGO Support for Neglected Tropical Diseases (NTDs) Treatment Initiatives”

• The increasing government and NGO support for neglected tropical diseases (NTDs) research and treatment programs is a major driver propelling the growth of the Global Neglected Tropical Diseases Treatment Market. With growing recognition of NTDs as a significant public health issue, both governments and international organizations are ramping up funding and resources to combat these diseases, which are often overlooked by mainstream healthcare systems.
  • For instance, in 2023, the World Health Organization (WHO) announced a renewed commitment to eliminating NTDs by 2030, with increased funding and collaboration with pharmaceutical companies. Their efforts include facilitating public-private partnerships to accelerate research, clinical trials, and the development of affordable treatments for diseases such as lymphatic filariasis, leprosy, and river blindness.
• This growing support is enabling research institutions and biopharmaceutical companies to innovate and develop more effective treatments for NTDs, focusing on both therapeutic efficacy and ease of distribution in low-resource settings. Additionally, the emphasis on collaborative efforts is improving access to treatments, which are often limited by geography and infrastructure in endemic regions.
• Furthermore, initiatives such as the Global Drug Facility for tuberculosis and the Medicines for Malaria Venture are paving the way for the development and equitable distribution of drugs, increasing the accessibility of life-saving treatments to populations that are most in need.
• This driver highlights the pivotal role of international cooperation in addressing global health disparities, which is expected to significantly accelerate the development of treatments and therapies for neglected tropical diseases, expanding the market and improving health outcomes in affected regions.

Restraint/Challenge

“Limited Healthcare Infrastructure and Access in Endemic Regions Hindering Treatment Delivery”

• Limited healthcare infrastructure and access in endemic regions pose a significant restraint on the delivery of Neglected Tropical Diseases (NTDs) treatment therapies. While there is considerable progress in developing effective treatments, the lack of adequate healthcare systems, diagnostic tools, and treatment facilities in many parts of the world hinders the reach and efficacy of these therapies. In regions where NTDs are most prevalent, basic healthcare infrastructure such as well-equipped clinics, trained medical personnel, and reliable transportation for patients is often lacking, which makes it difficult for patients to access advanced treatment options.
  • For instance, despite the availability of affordable drugs and treatments for diseases like schistosomiasis and leishmaniasis, many rural and remote areas in Sub-Saharan Africa and Southeast Asia face significant logistical challenges in delivering these medicines to affected populations. These regions often lack the necessary infrastructure to properly store, distribute, and administer treatments, leading to delays in treatment and low patient adherence.
• Addressing these challenges will require significant investment in healthcare infrastructure, including building and upgrading local clinics, improving transportation networks, and providing training for healthcare workers. Furthermore, international organizations and governments will need to strengthen healthcare systems to ensure that treatments can be delivered effectively to populations in need.
• While progress is being made through initiatives like the Global Fund and UNITAID, which are focused on strengthening healthcare infrastructure in developing regions, the lack of a robust healthcare system remains one of the biggest barriers to widespread treatment adoption.
• Overcoming these infrastructure challenges will be crucial in improving the accessibility and effectiveness of NTD treatments, ensuring that therapies reach the populations that need them the most.

Neglected Tropical Diseases Treatment Market Scope

The market is segmented on the basis of Disease Disease type, treatment, application, route of administration, end users and distribution channel.

• By Disease type

On the basis of Disease type, the Global Neglected Tropical Diseases Treatment Market is segmented into stem cell-based therapies, allogeneic therapies, autologous therapies, iPSC-derived therapies, and others. The autologous therapies segment is expected to dominate the market with the largest revenue share of 43.2% in 2025. This is driven by their widespread use in regenerative medicine, where cells or tissues are sourced from the patient’s own body, minimizing the risk of immune rejection and improving therapeutic outcomes. Autologous therapies are commonly used in treatments for conditions such as cardiovascular diseases, osteoarthritis, and neurological disorders, contributing to their established reputation for safety and effectiveness.

The mediterranean fever segment is anticipated to witness the fastest growth rate of 21.7% from 2025 to 2032. Allogeneic therapies, sourced from healthy donors, provide the advantage of being ready-to-use, which simplifies treatment and reduces time compared to autologous therapies. This makes them highly valuable in clinical environments, where quick access to treatments is critical. The growing adoption of allogeneic therapies, particularly for hematologic diseases, and their integration with cutting-edge biomanufacturing technologies, is expected to drive significant growth in this segment. The availability of off-the-shelf solutions will further accelerate their use, enabling faster treatment and boosting the overall expansion of the Global Neglected Tropical Diseases Treatment Market.

• By Treatment

On the basis of treatment, the Global Neglected Tropical Diseases Treatment Market is segmented into musculoskeletal disorders, cardiovascular diseases, neurological disorders, cancer treatment, and others. The drug segment is expected to hold the largest market revenue share in 2025, driven by the rising prevalence of osteoarthritis, osteoporosis, and other joint and bone-related conditions. Neglected Tropical Diseases Treatment therapies, especially those utilizing stem cells, are increasingly being explored for repairing damaged cartilage and bone tissues, offering promising alternatives for patients who do not respond well to conventional treatments.

The drug segment is anticipated to witness the fastest growth rate of 21.7% from 2025 to 2032. Stem cell therapies aimed at neurological conditions, including Parkinson's disease, Alzheimer's disease, and spinal cord injuries, have gained significant traction due to their potential to regenerate nerve cells and restore function. The increasing number of clinical trials, coupled with advancements in iPSC-derived therapies, are key factors driving this rapid growth. Additionally, these treatments stand to benefit from growing research funding, expanded regulatory support, and their potential for broader application in addressing complex neurological disorders, contributing to the accelerating growth of the segment.

• By Application

On the basis of application, the Global Neglected Tropical Diseases Treatment Market is segmented into musculoskeletal disorders, cardiovascular diseases, neurological disorders, cancer treatment, and others. The cardiovascular segment is expected to hold the largest market revenue share in 2025, driven by the increasing adoption of personalized medicine and the reduced risk of immune rejection when utilizing a patient’s own cells. These therapies are particularly favored in regenerative medicine for treating cardiovascular diseases, where the use of the patient’s own cells promotes tissue regeneration and recovery.

The cardiovascular segment is anticipated to witness the fastest CAGR from 2025 to 2032. Mesenchymal stem cells (MSCs), known for their versatility and regenerative potential, are gaining significant traction in the treatment of cardiovascular, musculoskeletal, and neurological diseases. MSCs can be sourced from a variety of tissues, such as bone marrow, adipose tissue, and umbilical cord blood. Their ability to differentiate into multiple cell Disease Disease types, reduce inflammation, and promote tissue repair is fueling their rapid growth in the market, particularly in both autologous and allogeneic therapeutic applications. This is driving further advancements and adoption in the treatment of complex diseases like cardiovascular conditions.

• By Route of Administration

On the basis of route of administration, the Global Neglected Tropical Diseases Treatment Market is segmented into hospitals, research institutions, pharmaceutical companies, biotech companies, and others. The oral segment is expected to account for the largest market revenue share in 2025, driven by the growing demand for convenient, patient-friendly treatment options in regenerative medicine and the increasing prevalence of chronic diseases. Oral therapies, particularly those utilizing stem cells and advanced drug delivery systems, are becoming increasingly important in treating conditions such as cardiovascular diseases, neurological disorders, and musculoskeletal injuries. These treatments offer the advantage of ease of administration, improving patient compliance and facilitating widespread use in outpatient settings.

The oral segment is anticipated to witness the fastest CAGR from 2025 to 2032. Research institutions are actively developing oral delivery formulations for stem cell therapies and regenerative treatments, driven by the need for more accessible and efficient treatment options. As the focus on precision medicine and personalized healthcare continues to grow, the development of oral treatments for neglected tropical diseases is gaining momentum. The potential for oral therapies to offer cost-effective, scalable solutions for patients, particularly in low-resource settings, is expected to contribute significantly to the segment's rapid growth in the coming years.

• By End User

On the basis of end user, the Global Neglected Tropical Diseases Treatment Market is segmented into hospitals, research institutions, pharmaceutical companies, biotech companies, and others. The hospitals segment is expected to hold the largest market revenue share in 2025, driven by the increasing demand for advanced treatments in regenerative medicine and the rising prevalence of chronic diseases. Neglected Tropical Diseases Treatment therapies, particularly those utilizing stem cells, are gaining traction for the treatment of conditions such as cardiovascular diseases, neurological disorders, and musculoskeletal injuries, making them a vital part of modern healthcare. Hospitals are adopting these therapies due to their ability to provide personalized and effective treatment options for patients, enhancing recovery and improving long-term outcomes.

The hospitals segment is anticipated to witness the fastest CAGR from 2025 to 2032. Hospitals are increasingly adopting advanced treatments for Neglected Tropical Diseases, driven by the growing demand for regenerative medicine and the need to address chronic and complex diseases. With the integration of cutting-edge therapies, such as stem cell-based treatments, hospitals are becoming key centers for the administration of personalized therapies for conditions like cardiovascular diseases, musculoskeletal disorders, and neurological conditions.

Neglected Tropical Diseases Treatment Market Regional Analysis

• North America is expected to dominate the Global Neglected Tropical Diseases Treatment Market, holding the largest revenue share of 40.01% in 2025. This dominance is attributed to significant advancements in regenerative medicine, a robust healthcare infrastructure, and the increasing demand for personalized and targeted treatments.
• The region's consumers prioritize the effectiveness, safety, and long-term benefits offered by Neglected Tropical Diseases Treatment therapies, particularly for chronic and degenerative conditions. The growing prevalence of diseases such as cardiovascular disorders, musculoskeletal conditions, and neurological diseases is driving a surge in demand for innovative therapeutic options.
• This market expansion is further supported by North America’s well-established healthcare system, substantial investments in stem cell research, and strong government backing for biotechnology innovations. These factors position the region as a key leader in the development, clinical application, and commercialization of Neglected Tropical Diseases Treatment therapies, with a continuous focus on personalized medicine and cutting-edge cell-based technologies.

U.S. Neglected Tropical Diseases Treatment Market Insight

The U.S. is expected to capture the largest revenue share of 81% within North America in the Global Neglected Tropical Diseases Treatment Market in 2025. This dominance is driven by rapid advancements in regenerative medicine, alongside the widespread adoption of innovative healthcare technologies. The increasing emphasis on personalized treatments for chronic and degenerative diseases, including cardiovascular, musculoskeletal, and neurological conditions, plays a significant role in propelling market growth. Additionally, the U.S. benefits from a robust healthcare infrastructure, strong investments in biotechnology, and a thriving research environment, which collectively accelerate the development and commercialization of Neglected Tropical Diseases Treatment therapies.  

Europe Neglected Tropical Diseases Treatment Market Insight

The European Neglected Tropical Diseases Treatment market is projected to experience significant growth during the forecast period, driven by the rising demand for advanced regenerative therapies and the increasing prevalence of chronic and degenerative diseases. The growing need for effective treatments in areas like cardiovascular, musculoskeletal, and neurological disorders is accelerating the adoption of Neglected Tropical Diseases Treatment therapies. The region's growing focus on personalized medicine, combined with robust investments in stem cell research, is further supporting this market expansion. European consumers and healthcare providers are increasingly drawn to the potential of these therapies to improve patient outcomes, reduce healthcare costs, and enhance quality of life. Notably, significant growth is being observed across hospitals, research institutions, and pharmaceutical companies, with Neglected Tropical Diseases Treatment therapies being integrated into clinical trials and established treatment protocols.

U.K. Neglected Tropical Diseases Treatment Market Insight

The U.K. Neglected Tropical Diseases Treatment market is expected to experience substantial growth, driven by increasing adoption of advanced regenerative therapies and the rising prevalence of chronic conditions. The demand for effective treatments in musculoskeletal, cardiovascular, and neurological disorders is fueling the market. The U.K.'s strong healthcare infrastructure and continued investments in stem cell research and personalized medicine are expected to boost market expansion. Furthermore, the growing focus on precision medicine and awareness of Neglected Tropical Diseases Treatment therapies’ benefits in tissue regeneration and disease treatment are encouraging healthcare providers and patients to embrace these innovative solutions.

Germany Neglected Tropical Diseases Treatment Market Insight

The German Neglected Tropical Diseases Treatment market is expected to grow significantly during the forecast period, driven by rising awareness of regenerative medicine and increasing demand for advanced treatments for chronic and degenerative diseases. Germany’s robust healthcare system, coupled with its focus on innovation and research, fosters the adoption of Neglected Tropical Diseases Treatment therapies, particularly for cardiovascular, musculoskeletal, and neurological disorders. The integration of these therapies in clinical settings and research institutions, along with a strong emphasis on personalized and precision medicine, supports market growth. Additionally, Germany’s commitment to sustainability and advanced medical technologies is aligning with the rising demand for regenerative treatments.

Asia-Pacific Neglected Tropical Diseases Treatment Market Insight

The Asia-Pacific Neglected Tropical Diseases Treatment market is expected to grow at the fastest CAGR of over 24% in 2025, fueled by rapid advancements in regenerative medicine, increasing healthcare demands, and rising investments in biotechnology, particularly in countries like China, Japan, and India. The region's growing emphasis on personalized and precision medicine is driving the demand for Neglected Tropical Diseases Treatment therapies, especially for chronic conditions such as cardiovascular, musculoskeletal, and neurological disorders. As Asia-Pacific emerges as a hub for stem cell research and clinical applications, improved accessibility and affordability are expanding the reach of these therapies to a broader patient base.  

Japan Neglected Tropical Diseases Treatment Market Insight

The Japan Neglected Tropical Diseases Treatment market is expanding due to the country’s strong emphasis on advanced healthcare technologies, rising demand for personalized treatments, and the increasing prevalence of chronic diseases. Japan’s focus on improving healthcare outcomes drives the adoption of Neglected Tropical Diseases Treatment therapies, particularly for musculoskeletal, cardiovascular, and neurological disorders. The integration of these therapies into clinical settings, research institutions, and healthcare systems is fostering market growth. Additionally, Japan’s aging population is expected to boost demand for regenerative treatments, enhancing quality of life and reducing invasive procedures. Ongoing investments in biotechnology and precision medicine will further drive therapy adoption.  

China Neglected Tropical Diseases Treatment Market Insight

The China Neglected Tropical Diseases Treatment market is expected to hold the largest market revenue share in Asia Pacific in 2025, driven by rapid advancements in healthcare technologies, increasing investments in regenerative medicine, and a growing middle class. China’s expanding healthcare sector and rising demand for effective treatments for chronic and degenerative diseases are driving the adoption of Neglected Tropical Diseases Treatment therapies. The country’s strong focus on healthcare innovation, government support for biotechnology research, and significant investments in stem cell-based treatments are fueling market growth. Additionally, the increasing prevalence of cardiovascular and musculoskeletal disorders and the growing demand for personalized medicine further accelerate adoption..

Neglected Tropical Diseases Treatment Market Share

The Neglected Tropical Diseases Treatment industry is primarily led by well-established companies, including:

• Emergent BioSolutions Inc. (U.S.)
• Moderna (U.S.)
• Valneva SE (France)
• Johnson & Johnson Services, Inc. (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Insud Pharma Group (Spain)
• Humanigen, Inc. (U.S.)
• Savant HWP, Inc. (U.S.)
• Bayer AG (Germany)
• Eisai Co., Ltd. (Japan)
• Oblita Therapeutics (China)
• GlaxoSmithKline plc (U.K.)
• Themis Bioscience GmbH (Austria)
• Novartis AG (Switzerland)
• Amneal Pharmaceuticals LLC (U.S.)
• Zydus Cadila (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Veru Inc. (U.S.
• Regeneron Pharmaceuticals, Inc. (U.S.
• Swedish Orphan Biovitrum AB (Sweden)

SKU-46715